Stayble's CEO, Andreas Gerward, presented (in Swedish) at Financial Stockholm on December 11, 2024

Stayble Therapeutics AB ("Stayble" or "the Company") CEO, Andreas Gerward, presented (in Swedish) the Company, the results from phase 1b, and the path forward at Financial Stockholm's event "Invest Like the Pros" on December 11, 2024. Watch the recorded presentation below:

https://www.youtube.com/watch?v=41H9eQ57mlc

For more information

Andreas Gerward, CEO of Stayble Therapeutics AB

Mail: andreas.gerward@stayble.se

Phone: +46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical pharmaceutical company developing the injection treatment STA363 for lumbar disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that targets the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. The treatment is aimed at patients who are not helped by physical therapy and painkillers and is a single injection that is expected to last a lifetime and requires minimal rehabilitation. After convincing data from previous pre-clinical and clinical studies (phase 1b and 2b) in degenerative disc disease, which show a volume reduction of the discs, the Company has successfully completed a phase 1b study for the treatment of herniated discs.

The company's Certified Adviser is Svensk Kapitalmarknadsgranskning AB.